Your browser doesn't support javascript.
loading
Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
Ratti, Francesca; Marino, Rebecca; Olthof, Pim B; Pratschke, Johann; Erdmann, Joris I; Neumann, Ulf P; Prasad, Raj; Jarnagin, William R; Schnitzbauer, Andreas A; Cescon, Matteo; Guglielmi, Alfredo; Lang, Hauke; Nadalin, Silvio; Topal, Baki; Maithel, Shishir K; Hoogwater, Frederik J H; Alikhanov, Ruslan; Troisi, Roberto; Sparrelid, Ernesto; Roberts, Keith J; Malagò, Massimo; Hagendoorn, Jeroen; Malik, Hassan Z; Olde Damink, Steven W M; Kazemier, Geert; Schadde, Erik; Charco, Ramon; de Reuver, Philip R; Groot Koerkamp, Bas; Aldrighetti, Luca.
Afiliação
  • Ratti F; Hepatobiliary Surgery Division, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milano, Italy.
  • Marino R; Hepatobiliary Surgery Division, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milano, Italy.
  • Olthof PB; Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Pratschke J; Department of Surgery, Charité-Universitätsmedizin, Berlin, Germany.
  • Erdmann JI; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
  • Neumann UP; Department of General, Gastrointestinal, Hepatobiliary and Transplant Surgery, RWTH Aachen University Hospital, Aachen, Germany.
  • Prasad R; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Jarnagin WR; Department of Hepatobiliary and Liver Transplant Surgery, Division of Surgery, St James's University Hospital, Leeds, United Kingdom.
  • Schnitzbauer AA; Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Cescon M; Department of General and Visceral Surgery, University Hospital, Goethe University, Frankfurt, Germany.
  • Guglielmi A; Department of General Surgery and Transplantation, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Lang H; Unit of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.
  • Nadalin S; Department of General, Visceral and Transplant Surgery, University Hospital Mainz, Mainz, Germany.
  • Topal B; Department of General and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Maithel SK; Department of Abdominal Surgery, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
  • Hoogwater FJH; Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA.
  • Alikhanov R; Department of Surgery, Section of Hepatobiliary Surgery & Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Troisi R; Department of Liver and Pancreatic Surgery, Moscow Clinical Scientific Center, Russia.
  • Sparrelid E; Department of Clinical Medicine and Surgery, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, Federico II University Hospital, Naples, Italy.
  • Roberts KJ; Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Malagò M; Department of Surgery, University Hospital Birmingham, Birmingham, United Kingdom.
  • Hagendoorn J; Department of HPB- and Liver Transplantation Surgery, University College London, Royal Free Hospitals, London, United Kingdom.
  • Malik HZ; Department of Surgery, Regional Academic Cancer Centre Utrecht, St Antonius Hospital, Nieuwegein and University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Olde Damink SWM; Department of Hepatobiliary Surgery, Aintree University Hospital, Liverpool University Hospitals, NHS Foundation Trust, Liverpool, United Kingdom.
  • Kazemier G; Department of General, Gastrointestinal, Hepatobiliary and Transplant Surgery, RWTH Aachen University Hospital, Aachen, Germany.
  • Schadde E; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Charco R; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
  • de Reuver PR; Department of Surgery, Cantonal Hospital Winterthur, Zurich, Switzerland.
  • Groot Koerkamp B; Department of HBP Surgery and Transplantation, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Spain.
  • Aldrighetti L; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Hepatology ; 79(2): 341-354, 2024 02 01.
Article em En | MEDLINE | ID: mdl-37530544
ABSTRACT

BACKGROUND:

While resection remains the only curative option for perihilar cholangiocarcinoma, it is well known that such surgery is associated with a high risk of morbidity and mortality. Nevertheless, beyond facing life-threatening complications, patients may also develop early disease recurrence, defining a "futile" outcome in perihilar cholangiocarcinoma surgery. The aim of this study is to predict the high-risk category (futile group) where surgical benefits are reversed and alternative treatments may be considered.

METHODS:

The study cohort included prospectively maintained data from 27 Western tertiary referral centers the population was divided into a development and a validation cohort. The Framingham Heart Study methodology was used to develop a preoperative scoring system predicting the "futile" outcome.

RESULTS:

A total of 2271 cases were analyzed among them, 309 were classified within the "futile group" (13.6%). American Society of Anesthesiology (ASA) score ≥ 3 (OR 1.60; p = 0.005), bilirubin at diagnosis ≥50 mmol/L (OR 1.50; p = 0.025), Ca 19-9 ≥ 100 U/mL (OR 1.73; p = 0.013), preoperative cholangitis (OR 1.75; p = 0.002), portal vein involvement (OR 1.61; p = 0.020), tumor diameter ≥3 cm (OR 1.76; p < 0.001), and left-sided resection (OR 2.00; p < 0.001) were identified as independent predictors of futility. The point system developed, defined three (ie, low, intermediate, and high) risk classes, which showed good accuracy (AUC 0.755) when tested on the validation cohort.

CONCLUSIONS:

The possibility to accurately estimate, through a point system, the risk of severe postoperative morbidity and early recurrence, could be helpful in defining the best management strategy (surgery vs. nonsurgical treatments) according to preoperative features.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangite / Tumor de Klatskin / Colangiocarcinoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangite / Tumor de Klatskin / Colangiocarcinoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália
...